| May. 08, 2008 | Print This | Email This |
| |
|
|
|
"As a pediatric anesthesiology research nurse, I regularly witness children's pain caused by blood draws and IV insertions," said survey author Terri Voepel-Lewis, MSN, RN, C.S. Mott Children's Hospital. "This survey reinforces the enormous positive impact nurses can have on a patient's experience, simply by using pharmacologic and other management options available to manage peripheral venous access pain."
Data were collected by an on-line survey administered to a national sample of nurse participants. The survey was distributed via e-mailed invitation to the membership of the Emergency Nurses Association, the Infusion Nurses Society, and the Society of Pediatric Nurses. Participants were asked to rate the importance of managing blood draw and IV pain, the impact that these procedures have on patient and nurse satisfaction, and their attitudes on the value of available pharmacologic and non-pharmacologic interventions. A total of 2,187 nurses completed the survey.(1)
Nearly all (96 percent) participants agree that inserting an IV line into a fearful, anxious child can be challenging -- a situation that is encountered 76 percent of the time.(1) As reported by survey respondents, children receiving an IV insertion need to be restrained about 74 percent of the time.(1) In addition, the survey found that children who do not receive a topical local anesthetic (TLA) prior to blood draws and IV insertions experience distress and anxiety 72 percent of the time.(1) Nearly all survey participants (92 percent) agreed that patients and their families would benefit from the use of a fast-acting TLA for such procedures.(1)
Most surveyed nurses (96 percent) reported using non-pharmacologic options to manage children's pain. Despite the fact that 66 percent of respondents reported having experience using pharmacologic interventions, they indicated that TLAs are employed less than a third (28 percent) of the time. Primary reasons cited for not using pharmacologic interventions include their association with slow onset of action, treatment delays, and vasoconstriction, as well as lack of physician authorization.(1)
"This survey reinforces a core belief of the children's pain community -- that all children deserve to be offered appropriate medical resources and comfort for peripheral venous access procedures," said William T. Zempsky, M.D., associate professor, Department of Pediatrics,
About Anesiva and its Diverse Pipeline of Pain Products
Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. The second product in Anesiva's pipeline, Adlea(TM), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.
(1) Papa AM, Morgan R, Zempsky WT et al. Nurse and Patient Satisfaction Negatively Impacted by Inadequate Peripheral Venous Access Pain Management in Children. To be presented by Papa et al. at: American Pain Society; May 8-10, 2008; Tampa, Florida. (2) Anesiva, Data on File. (3) Wong DL, Baker CM. Pain in children: comparison of assessment scales. Pediatr Nurs. 1988;14(1):9-17. (4) American Academy of Pediatrics Committee on Psychosocial Aspects of Child and Family Health and American Pain Society Task Force on Pain in Infants, Children, and Adolescents. The assessment and management of acute pain in infants, children, and adolescents. Pediatrics. 2001;108:793-797. (5) MacLean S, Obispo J, Young KD. The gap between pediatric emergency department procedural pain management treatments available and actual practice. Pediatr Emerg Care. 2007;23(2):87-93.
Anesiva, Inc.CONTACT: Carol DeGuzman, Investor Relations of Anesiva, Inc.,
+1-650-246-6898, deguzman@anesiva.com; or Melissa Lang, Media Relations of
WeissComm Partners, +1-212-301-7208,
Web site: http://www.anesiva.com/

